Objective:

To evaluate the efficacy, safety and costs of acquisition, preparation and dispensing of PRGF-Endoret eye drops, as well as patient satisfaction in patients with pathological dry eye.

Methodology:

Retrospective observational study. All patients for whom PRGF-Endoret were prescribed between February 2019 and January 2020 for the treatment of various disorders with ocular sequence as a symptom were included. Demographic and clinical data were obtained from the electronic medical record (Orion Clinic). In addition, an anonymous survey was carried out evaluating the frequency of various symptoms, the difficulty, safety and satisfaction with the treatment.

Results:

24 patients were studied. 62.5% were women, with a median age of 64 years. 79% had been diagnosed with keratitis and/or corneal ulcer. In 75% of the cases, the clinical evolution was favourable after three months. 100% of the patients were satisfied. Regarding symptoms, 100% perceived an improvement in dry eyes, 80% in light discomfort and 60% in pain. 50% of the patients had previously received autologous serum, of which 82% had a favourable evolution with the change of treatment.

Conclusion:

PRGF-Endoret improved dry eye symptoms in our patients being effective and safe, with high satisfaction from the patients. Although evaluating direct healthcare costs is more expensive than the autologous serum alternative, quality of life and indirect costs should be considered.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )